215 related articles for article (PubMed ID: 14871967)
21. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
24. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
25. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI
Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210
[TBL] [Abstract][Full Text] [Related]
26. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.
Slovin SF; Ragupathi G; Adluri S; Ungers G; Terry K; Kim S; Spassova M; Bornmann WG; Fazzari M; Dantis L; Olkiewicz K; Lloyd KO; Livingston PO; Danishefsky SJ; Scher HI
Proc Natl Acad Sci U S A; 1999 May; 96(10):5710-5. PubMed ID: 10318949
[TBL] [Abstract][Full Text] [Related]
27. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
28. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
29. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
Wang ZG; Williams LJ; Zhang XF; Zatorski A; Kudryashov V; Ragupathi G; Spassova M; Bornmann W; Slovin SF; Scher HI; Livingston PO; Lloyd KO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2719-24. PubMed ID: 10716997
[TBL] [Abstract][Full Text] [Related]
30. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Livingston PO; Adluri S; Helling F; Yao TJ; Kensil CR; Newman MJ; Marciani D
Vaccine; 1994 Nov; 12(14):1275-80. PubMed ID: 7856291
[TBL] [Abstract][Full Text] [Related]
32. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
34. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Gilewski T; Ragupathi G; Bhuta S; Williams LJ; Musselli C; Zhang XF; Bornmann WG; Spassova M; Bencsath KP; Panageas KS; Chin J; Hudis CA; Norton L; Houghton AN; Livingston PO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3270-5. PubMed ID: 11248068
[TBL] [Abstract][Full Text] [Related]
35. On the emerging role of chemistry in the fashioning of biologics: synthesis of a bidomainal fucosyl GM1-based vaccine for the treatment of small cell lung cancer.
Nagorny P; Kim WH; Wan Q; Lee D; Danishefsky SJ
J Org Chem; 2009 Aug; 74(15):5157-62. PubMed ID: 19555091
[TBL] [Abstract][Full Text] [Related]
36. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A
J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of widely consumed botanicals as immunological adjuvants.
Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
[TBL] [Abstract][Full Text] [Related]
39. The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.
Hung JT; Chen IJ; Ueng SH; Huang CS; Chen SC; Chen MY; Lin YC; Lin CY; Campbell MJ; Rugo HS; Yu AL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732348
[TBL] [Abstract][Full Text] [Related]
40. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]